Gastroenterology
Few markets have moved faster than gastroenterology. The question for brand teams is not whether the landscape is changing, but whether their market intelligence is keeping up.
Subscribe for Gastroenterology updates
About Gastroenterology
Gastroenterology has undergone more structural change in the past three years than in the prior decade. The emergence of effective therapies in inflammatory bowel disease has intensified competitive pressure across Crohn’s disease and ulcerative colitis. The FDA approval of the first MASH treatment marked a watershed moment for a condition long defined by unmet need, and GLP-1-based therapies, now reshaping treatment pathways across obesity, metabolic disease, and chronic GI conditions, have introduced a new class of commercial dynamics that gastroenterology teams are still calibrating.
Spherix works with 9 of the top 10 global pharmaceutical companies in gastroenterology, drawing on more than 40 years of combined team experience. The Spherix GI community is a group of practicing gastroenterologists and hepatologists across the US, screened and maintained continuously by Spherix’s Community team, so every data point reflects what is actually happening at the point of care.
INDICATIONS COVERED
- Celiac Disease
- Cholestatic Pruritus (CP)
- Crohn's Disease (CD)
- Eosinophilic Esophagitis (EoE)
- Irritable Bowel Syndrome (IBS)
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Obesity
- Primary Biliary Cholangitis (PBC)
- Primary Sclerosing Cholangitis (PSC)
- Ulcerative Colitis (UC)
The insights that inform confident, strategic decisions
The Spherix three-perspective lens applied to gastroenterology:
Physician
How are gastroenterologists sequencing biologics in IBD as class competition intensifies? Where is prescriber intent shifting in MASH as the pipeline advances toward approval?
Patient
Where do patient and physician views on treatment burden diverge in CD and UC? What is driving non-adherence and switching behavior in chronic GI conditions?
payer (market access)
How are payers managing formulary placement and step-edit criteria as the IBD biologic class matures? What does early MASH coverage look like across commercial and government plans?
Spherix clients have exclusive access to
Research products
Therapeutic expertise and advisory
Direct access to Spherix gastroenterology specialists for strategic working sessions, commercial pressure-testing, and on-demand advisory – the expertise behind the research, available to your team when you need it.
Customization and targeting
AI-assisted synthesis
Every output is reviewed and validated by a gastroenterology specialist before delivery. Spherix's AI-assisted intelligence layer draws on more than a decade of GI data simply to get that specialist to an answer faster, and to help identify the right specialists for every wave.
Related Articles
Meet the Team
